Synthesis, in vitro anti-breast cancer activity, and intracellular decomposition of amino acid methyl ester and alkyl amide phosphoramidate monoesters of 3'-azido-3'-deoxythymidine (AZT)

Journal of Medicinal Chemistry

Volumn 43, Issue 11, 2000, Pages 2266-2274

  Iyer, Vidhya V ^a   Griesgraber, George W ^a   Radmer, Matthew R ^a   McIntee, Edward J ^a   Wagner, Carston R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; METHYL GROUP; PHOSPHORAMIDIC ACID DERIVATIVE; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CYTOTOXICITY; DECOMPOSITION; HUMAN; HUMAN CELL; STEREOCHEMISTRY; SYNTHESIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; ESTERS; FEMALE; HUMANS; TUMOR CELLS, CULTURED; ZIDOVUDINE;

EID: 0034214201     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000110g     Document Type: Article

References (47)

1. Horwitz, J. P.; Chua, J.; Noel, M. J. The monomesylation of 1-(2′-deoxy-β-D-xylofuranosyl)thymine. J. Org. Chem. 1964, 29, 2076-2078.
2. Hirsh, M. S. Azidothymidine. J. Infect. Dis. 1988, 157, 427-431.
3. Brunetti, I.; Falcone, A.; Calabresi, P.; Goulette, F. A.; Darnowski, J. W. 5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies. Cancer Res. 1990, 50, 4026-4031.
4. DeLap, R.; Swain, S.; Ong, D.; Rosen, N.; Bodurian, E.; Steakley, C.; Nazzaro, D.; King, D.; Santore, G. A Phase I study of zidovudine (AZT), leucovorin (Lv), and fluorouracil (FU) in patients with advanced cancer (meeting abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1991, 10, A295.
5. Browne, M. J.; Beitz, J.; Clark, J. W.; Cummings, F. J.; Weitberg, A.; Murray, C.; Darnowski, J. W. A Phase I study of zidovudine (AZT) combined with methotrexate in patients (pts) with advanced cancer (Meeting abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1993, 12, A451.
6. Darnowski, J. W.; Goulette, F. A. 3′-Azido-3′-deoxythymidine cytotoxicity and metabolism in the human colon tumor cell line HCT-8. Biochem. Pharmacol. 1994, 48, 1797-1805.
7. Doroshow, J. H.; Newman, E.; Carroll, M.; Ahn, C.; Akman, S.; Chow, W.; Coluzzi, P.; Hamasaki, V.; Leong, L.; Margolin, K.; et al. Phase I trial of continuous infusion zidovudine (AZT) and cisplatin in patients with advanced cancer (Meeting abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol 1994, 13, A377.
8. Wagner, C. R.; Ballato, G.; Akanni, A. O.; McIntee, E. J.; Larson, R. S.; Chang, S. L.; Abulhajj, Y. J. Potent growth inhibitory activity of zidovudine on cultured human breast cancer cells and rat mammary tumors. Cancer Res. 1997, 57, 2341-2345.
9. Nyce, J.; Leonard, S.; Canupp, D.; Schulz, S.; Wong, S. Epigenetic mechanisms of drug resistance: Drug-induced DNA hypermethylation and drug resistance. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 2960-2964.
10. Sommadossi, J. P. Nucleoside analogues: Similarities and differences. Clin. Infect. Dis. 1993, 16, S7-15.
11. Resetar, A.; Minick, D.; Spector, T. Glucuronidation of 3′-azido-3′-deoxythymidine catalyzed by human liver UDP-glucurono-syltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. Biochem. Pharmacol. 1991, 42, 559-568.
12. Acosta, E. P.; Page, L. M.; Fletcher, C. V. Clinical Pharmacokinetics of zidovudine - An update. Clin. Pharmacokinet. 1996, 30, 251-262.
13. Hostetler, K. Y.; Stuhmiller, L. M.; Lenting, H. B. M.; Van den Bosch, H.; Richman, D. D. Synthesis and antiretroviral activity of phospholipid analogues of azidothymidine and other antiviral nucleosides. J. Biol. Chem. 1990, 265, 6112-6117.
14. Busso, M.; Mian, A. M.; Hahn, E. F.; Resnick, L. Nucleotide dimers suppress HIV expression in vitro. AIDS Res. Hum. Retrovir. 1988, 4, 449-455.
15. Schinazi, R. F.; Sommadossi, J. P.; Saalmann, V.; Cannon, D. L.; Xie, M. Y.; Hart, G. C.; Smith, G. A.; Hahn, E. F. Activities of 3′-azido-3′-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immmunodeficiency virus Type-1. Antimicrob. Agents Chemother. 1990, 34, 1061-1067.
16. Khamnei, S.; Torrence, P. F. Neighboring group catalysis in the design of nucleotide prodrugs. J. Med. Chem. 1996, 39, 4109-4115.
17. Herdewijn, P.; Balzarini, J.; De Clerq, E.; Pauwels, R.; Baba, M.; Broder, S.; Vanderhaeghe, H. 3′-substituted 2′,3′-dideoxy-nucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. J. Med. Chem. 1987, 30, 1270-1278.
18. McGuigan, C.; Pathirana, R. N.; Davies, M. P. H.; Balzarini, J.; De Clercq, E. Diaryl phosphate derivatives act as pro-drugs of AZT with reduced cytotoxicity compared to the parent nucleoside. Bioorg. Med. Chem. Lett. 1994, 4, 427-430.
19. Gouyette, C.; Neumann, J. M.; Fauve, R.; Huynh, D. T. 6-and 1-Substituted mannosyl phosphotriesters as lipophilic macrophage-targeted carriers of antiviral nucleosides. Tetrahedron Lett. 1989, 30, 6019-6022.
20. Henin, Y.; Gouyette, C.; Schwartz, O.; Debouzy, J. C.; Neumann, J. M.; Huynh, D. T. Lipophilic glycosyl phosphotriester derivatives of AZT: synthesis, NMR transmembrane transport study and antiviral activity. J. Med. Chem. 1991, 34, 1830-1837.
21. Perigaud, C.; Gosselin, G.; Lefebvre, I.; Girardet, J. L.; Benzaria, S.; Barber, I.; Imbach, J. L. Rational design for cytosolic delivery of nucleoside monophosphates: "SATE" and "DTE" as enzymelabile transient phosphate protecting groups. Bioorg. Med. Chem. Lett. 1993, 3, 2521-2526.
22. Lefebvre, I.; Perigaud, C.; Pompon, A.; Aubertin, A. M.; Girardet, J. L.; Kirn, A.; Gosselin, G.; Imbach, J. L. Mononucleoside phosphotriester derivatives with S-Acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate. J. Med. Chem. 1995, 38, 3941-3950.
23. Puech, F.; Gosselin, G.; Lefebvre, I.; Pompon, A.; Aubertin, A. M.; Kirn, A.; Imbach, J. L. Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process. Antiviral Res. 1993, 22, 155-174.
24. Farquhar, D.; Nowak, B.; Khan, S.; Plunkett, W. A strategy to introduce therapeutic nucleoside 5′-phosphates into cells. Antiviral Res. 1991, 15, 143.
25. Sastry, J. K.; Nehete, P. N.; Khan, S.; Nowak, B. J.; Plunkett, W.; Arlinghaus, R. B.; Farquhar, D. Membrane-permeable dideoxyuridine 5′-monophosphate analogue inhibits human immunodeficiency virus infection. Mol. Pharmacol. 1992, 41, 441-445.
26. Pompon, A.; Lefebvre, I.; Imbach, J. L.; Kahn, S.; Farquhar, D. Decomposition pathways of the mono-and bis(pivaloyloxymethyl) esters of azidothymidine 5′-monophosphate in cell culture medium: an application of the "on-line ISRP-cleaning" HPLC technique. Antiviral Chem. Chemother. 1994, 5, 91-98.
27. Thomson, W.; Nicholls, D.; Irwin, W. J.; Al-Mushadani, J. S.; Freeman, S.; Karpas, A.; Petrik, J.; Mahmood, N.; Hay, A. J. Synthesis, bioactivation and anti-HIV activity of the bis(4-acyloxybenzyl) and mono(4-acyloxybenzyl) esters of the 5′-monophosphate of ***AZT***. J. Chem. Soc., Perkin Trans. 1993, 1, 1239-1245.
28. McGuigan, C.; O'Connor, T. J.; Nichols, S. R.; Nickson, C.; Kinchington, D. Synthesis and anti-HIV activity of some novel substituted dialkyl phosphate derivatives of AZT and ddCyd. Antiviral Chem. Chemother. 1990, 1, 355-360.
29. McGuigan, C.; Devine, K. G.; O'Connor, T. J.; Galpin, S. A.; Jeffries, D. J.; Kinchington, D. Synthesis and evaluation of some novel phosphoramidate derivatives of 3′-azido-3′-deoxythymidine (AZT) as anti-HIV compounds. Antiviral Chem. Chemother. 1990, 1, 107-113.
30. Abraham, T. W.; Wagner, C. R. A phosphoramidite-based synthesis of phosphoramidate amino acid diesters of antiviral nucleosides. Nucleosides Nucleotides 1994, 13, 1891-1903.
31. Wagner, C. R.; McIntee, E. J.; Schinazi, R. F.; Abraham, T. W. Aromatic amino acid phosphoramidate di-and triesters of 3′-azido-3′-deoxythymidine (AZT) are nontoxic inhibitors of HIV-1 replication. Bioorg. Med. Chem. Lett. 1995, 5, 1819-1824.
32. Wagner, C. R.; Chang, S. L.; Griesgraber, G. W.; Song, H.; McIntee, E. J.; Zimmerman, C. L. Antiviral nucleoside drug delivery via amino acid phosphoramidates. Nucleosides Nucleotides 1999, 18, 913-919.
33. McIntee, E. J.; Remmel, R. P.; Schinazi, R. F.; Abraham, T. W.; Wagner, C. R. Probing the mechanism of action and decomposition of amino acid phosphomonoester amidates of antiviral nucleoside prodrugs. J. Med. Chem. 1997, 40, 3323-3331.
34. Kers, I.; Stawinski, J.; Kraszewski, A. A new synthetic method for the preparation of nucleoside phosphoramidate analogues with the nitrogen atom in bridging positions of the phosphoramidate linkage. Tetrahedron Lett. 1998, 39, 1219-1222.
35. Jankowska, J.; Sobkowski, M.; Stawinski, J.; Kraszewski, A. Studies on aryl H-phosphonates. 1. An efficient method for the preparation of deoxyribo-and ribonucleoside 3′-H-phosphonate monoesters by transesterification of diphenyl H-phosphonate. Tetrahedron Lett. 1994, 35, 3355-3358.
36. Balzarini, J.; Herdewijn, P.; De Clercq, E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 1989, 264, 6127-6133.
37. Agarwal, R. P.; Mian, A. M. Thymidine and zidovudine metabolism in chronically zidovudine-exposed cells in vitro. Biochem. Pharmacol. 1991, 42, 905-911.
38. Furman, P. A.; Fyfe, J. A.; St Clair, M. H.; Weinhold, K.; Rideout, J. L.; Freeman, G. A.; Lehrman, S. N.; Bolognesi, D. P.; Broder, S.; Mitsuya, H.; et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci., U.S.A. 1986, 83, 8333-8337.
39. Frick, L. W.; Nelson, D. J.; St. Clair, M. H.; Furman, P. A.; Krenitsky, T. A. Effects of 3′-azido-3′-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells. Biochem. Biophys. Res. Commun. 1988, 154, 124-129.
40. Fridland, A.; Connelly, M. C.; Ashmun, R. Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3′-azido-3′-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol. Pharmacol. 1990, 37, 665-670.
41. Antonelli, G.; Turriziani, O.; Verri, A.; Narciso, P.; Ferri, F.; Doffizi, G.; Dianzani, F. Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. AIDS Res. Hum. Retrovir. 1996, 12, 223-228.
42. Tornevik, Y.; Ullman, B.; Balzarini, J.; Wahren, B.; Eriksson, S. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem. Pharmacol. 1995, 49, 829-837.
43. Cinatl Jr, J.; Groschel, B.; Zehner, R.; Cinatl, J.; Perigaud, C.; Gosselin, G.; Imbach, J. L.; Doerr, H. W. Human immunodeficiency virus resistant to AZT in MOLt4/8 cells is associated with a lack of AZT phosphorylation and is bypassed by AZT-monophosphate SATE prodrugs. Antiviral Chem. Chemother. 1997, 8, 343-352.
44. Wagner, C. R.; McIntee, E. J.; Schinazi, R. F.; Abraham, T. W. Aromatic amino acid phosphoramidate di-and triesters of 3′-azido-3′-deoxythymidine (AZT) are nontoxic inhibitors of HIV-1 replication. Bioorg. Med. Chem. Lett. 1995, 5, 1819-1824.
45. Abraham, T. W.; McIntee, E. J.; Iyer, V. V.; Schinazi, R. F.; Wagner, C. R. Synthesis, biological activity and decomposition studies of amino acid phosphomonester amidates of acyclovir. Nucleosides Nucleotides 1997, 16, 2079-2092.
46. Davidsohn, I.; Nelson, D. A. in Clinical Diagnosis; Davidsohn, I., Henry, J. B., Eds.; W. B. Saunders: Philadelphia, PA, 1969, pp 140-157.
47. Shier, W. T. The final steps to toxic cell death. J. Toxicol. - Toxin Rev. 1985, 4, 191-249.